Moody Aldrich Partners LLC reduced its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 26.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 43,649 shares of the company’s stock after selling 15,952 shares during the quarter. Protagonist Therapeutics accounts for approximately 1.2% of Moody Aldrich Partners LLC’s holdings, making the stock its 18th largest holding. Moody Aldrich Partners LLC’s holdings in Protagonist Therapeutics were worth $6,150,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Protagonist Therapeutics during the 2nd quarter worth approximately $1,263,535,000. Johnson & Johnson acquired a new stake in Protagonist Therapeutics in the second quarter valued at approximately $300,220,852. Jupiter Topco LLC acquired a new stake in Protagonist Therapeutics in the second quarter valued at approximately $261,039,000. Bank of America Corp DE purchased a new stake in shares of Protagonist Therapeutics during the second quarter valued at approximately $162,357,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Protagonist Therapeutics during the second quarter valued at approximately $117,783,000. 98.63% of the stock is owned by institutional investors and hedge funds.
Protagonist Therapeutics Stock Performance
NASDAQ:PTGX opened at $142.14 on Thursday. The stock has a market cap of $9.20 billion, a price-to-earnings ratio of 138.00 and a beta of 1.53. Protagonist Therapeutics, Inc. has a one year low of $75.44 and a one year high of $160.81. The business’s 50-day simple moving average is $143.26 and its 200 day simple moving average is $115.82.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on PTGX shares. Wall Street Zen cut shares of Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 10th. Citigroup raised their price target on shares of Protagonist Therapeutics from $175.00 to $182.00 and gave the company a “buy” rating in a report on Monday, August 31st. BMO Capital Markets raised their price target on shares of Protagonist Therapeutics from $178.00 to $190.00 and gave the company an “outperform” rating in a report on Tuesday, September 1st. Weiss Ratings downgraded shares of Protagonist Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 23rd. Finally, The Goldman Sachs Group raised shares of Protagonist Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $110.00 to $186.00 in a research note on Monday, August 10th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $163.27.
Get Our Latest Stock Report on PTGX
Insider Activity at Protagonist Therapeutics
In other Protagonist Therapeutics news, CEO Dinsesh Patel sold 7,278 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $144.10, for a total value of $1,048,759.80. Following the transaction, the chief executive officer directly owned 522,968 shares of the company’s stock, valued at $75,359,688.80. This represents a 1.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Asif Ali sold 58,629 shares of the company’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $141.78, for a total value of $8,312,419.62. Following the completion of the transaction, the chief financial officer directly owned 59,003 shares in the company, valued at approximately $8,365,445.34. The trade was a 49.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 283,629 shares of company stock worth $41,443,786 over the last 90 days. 5.19% of the stock is owned by company insiders.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc is a biopharmaceutical company focused on discovering and developing peptide-based medicines for immune-mediated and hematologic diseases. The company uses its proprietary peptide technology platform to design therapies intended to act on specific biological pathways and receptors.
Its leading program is icotrokinra, also known as JNJ-2113, an oral, targeted inhibitor of the interleukin-23 receptor being developed in collaboration with Janssen Pharmaceuticals for inflammatory and immune-mediated conditions, including psoriasis and inflammatory bowel diseases.
Featured Articles
- Five stocks we like better than Protagonist Therapeutics
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report).
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
